GOODWIN BIOTECHNOLOGY INC. COMPLETES cGMP MANUFACTURING OF AREVA Med’s CONJUGATE

USA - Plantation, FL, September 14th, 2009 – Goodwin Biotechnology Inc. (GBI) announced today the completion of the cGMP manufacturing and vialing of AREVA Med’s monoclonal antibody-chelator conjugate. As part of AREVA Med’s Lead-212 (212Pb) initiative, the conjugate will be used in Phase I clinical trials to treat several types of deadly forms of cancers. AREVA Med will benefit from the vast expertise in the nuclear industry from AREVA, its parent company, that allowed for the production of this radioisotope previously considered a scarce resource.

David Fischer, EVP of GBI, said “We are very pleased to have completed the manufacturing of AREVA Med’s conjugate. After some promising pre-clinical data, we look forward to seeing the outcome of the first in man studies.”

About Goodwin Biotechnology Inc.
GBI is one of the earliest biologics contract manufacturing organizations (CMOs), established in 1992. GBI specializes in process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical studies and clinical trials. GBI’s clients include small to midsized biotech companies throughout North America and Europe, as well as universities, renowned cancer research institutes and various branches of the U.S. government. GBI offers its clients the experience of an established U.S. Contract Manufacturing Organization, and provides services in a fully integrated offering, including process development, cell banking, cGMP manufacturing, conjugation, vialing, and distribution to the clinical trial sites. www.goodwinbio.com

About AREVA Med LLC.
AREVA Med LLC is a subsidiary of AREVA with manufacturing facilities in 43 countries and a sales network in more than 100 countries. AREVA offers customers reliable technological solutions for CO2-free power generation and electricity transmission and distribution. AREVA is the world leader in nuclear power and the only company to cover all industrial activities in this field. Our 75,000 employees are committed to continuous improvement on a daily basis, making sustainable development the focal point of the group’s industrial strategy. AREVA’s businesses help meet the 21st century’s greatest challenges: making energy available to all, protecting the planet, and acting responsibly towards future generations. www.areva.com

For more information, please contact:
AREVA Med LLC
4800 Hampden Lane, Suite 1100
Bethesda, Maryland 20814
Patrick Bourdet, President & CEO
(301) 841-1600
patrick.bourdet@areva.com

Goodwin Biotechnology Inc.
1850 NW 69 Avenue
Plantation, Florida 33313
David Fischer, EVP
(954) 327-9613
dfischer@goodwinbio.com